Literature DB >> 15059884

Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil.

Lee W Wattenberg1, Timothy S Wiedmann, Richard D Estensen.   

Abstract

Research aimed at identifying effective chemopreventive compounds active against carcinogenesis of the upper respiratory tract (URT) has been largely unsuccessful. We are addressing this problem by efforts at agent identification and by using aerosol delivery. Two compounds, difluoromethylornithine (DFMO) and 5-fluorouracil (5-FU) were investigated. DFMO is an irreversible inhibitor of ornithine decarboxylase, an enzyme important in cell proliferation. It has been used widely by oral administration for chemoprevention. 5-FU is a pyrimidine analog used extensively as a chemotherapeutic agent. It is generally administered i.v. and can cause considerable toxicity. However, aerosol administration for therapy of lung cancer in humans has been reported to be without adverse effects (Tatsumura et al., Br J Cancer 1993;68:1146-9). The experimental model used herein entailed six intratracheal administrations of methylnitrosourea (MNU) to hamsters. Each of the test agents was started about 1 week after MNU and was continued for 29 weeks with DFMO. Infiltrating squamous cell carcinomas of the URT occurred in 92% of the controls and were reduced by 50% in animals receiving DFMO (P = 0.0001). The experiment with 5-FU was of shorter duration being terminated 20 weeks after MNU. Thirty percent of the controls had infiltrating carcinomas and were reduced by 60% in animals receiving 5-FU (P = 0.0274). Both compounds resulted in a significant increase in the percent of cancer-free animals. These two agents may have selected use in subjects at high risk of cancer of the URT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059884     DOI: 10.1158/0008-5472.can-03-4032

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  High-frequency ultrasonic atomization for drug delivery to rodent animal models - optimal particle size for lung inhalation of difluoromethyl ornithine.

Authors:  Guifang Zhang; Chris Fandrey; Amir Naqwi; Timothy Scott Wiedmann
Journal:  Exp Lung Res       Date:  2008-06       Impact factor: 2.459

2.  The use of animal models for cancer chemoprevention drug development.

Authors:  Vernon E Steele; Ronald A Lubet
Journal:  Semin Oncol       Date:  2010-08       Impact factor: 4.929

3.  Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice.

Authors:  Donna E Seabloom; Arthur R Galbraith; Anna M Haynes; Jennifer D Antonides; Beverly R Wuertz; Wendy A Miller; Kimberly A Miller; Vernon E Steele; Chen S Suen; M Gerard O'Sullivan; Frank G Ondrey
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-19

4.  Preparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery.

Authors:  Pardis Kalantarian; Abdolhosein Rouholamini Najafabadi; Ismaeil Haririan; Alireza Vatanara; Yadollah Yamini; Majid Darabi; Kambiz Gilani
Journal:  Int J Nanomedicine       Date:  2010-10-05

5.  Effect of dietary green tea extract and aerosolized difluoromethylornithine during lung tumor progression in A/J strain mice.

Authors:  Marshall W Anderson; Colleen Goodin; Yu Zhang; Sangmi Kim; Richard D Estensen; Timothy S Wiedmann; Padmini Sekar; C Ralph Buncher; Jane C Khoury; Joel R Garbow; Ming You; Jay W Tichelaar
Journal:  Carcinogenesis       Date:  2008-05-29       Impact factor: 4.944

6.  Risk of second cancer after initial treatment of breast cancer: An Osaka Cancer Registry Database study.

Authors:  Yumi Kamigaki; Koji Kawakami
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

Review 7.  Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers.

Authors:  Stephen S Hecht; Fekadu Kassie; Dorothy K Hatsukami
Journal:  Nat Rev Cancer       Date:  2009-07       Impact factor: 60.716

Review 8.  Inhaled chemotherapy in lung cancer: future concept of nanomedicine.

Authors:  Paul Zarogoulidis; Ekaterini Chatzaki; Konstantinos Porpodis; Kalliopi Domvri; Wolfgang Hohenforst-Schmidt; Eugene P Goldberg; Nikos Karamanos; Konstantinos Zarogoulidis
Journal:  Int J Nanomedicine       Date:  2012-03-22

9.  Thymoquinone and Difluoromethylornithine (DFMO) Synergistically Induce Apoptosis of Human Acute T Lymphoblastic Leukemia Jurkat Cells Through the Modulation of Epigenetic Pathways.

Authors:  Mahmoud Alhosin; Syed Shoeb I Razvi; Ryan A Sheikh; Jalaluddin A Khan; Mazin A Zamzami; Hani Choudhry
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.